IVVD Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 2.32%, SMA50 -19.26%, SMA200 16.05%). The stock’s 14-day RSI is 44.63 (neutral), while the ATR of 0.14 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -44.62% below its high and over 269.57% above its low. Average 10-day trading volume of 2.97 million shares is in line with the 3-month average of 2.75 million, indicating normal recent market interest.

Invivyd, Inc. has 120.14 million shares outstanding. The public float is 51.82 million shares, elevated short interest at 4.69% of float. This equals 3.33 million shares. The short ratio is 4.79 days. Institutional investors hold 75.18% of the float. Insiders own 19.2%. Adimab, LLC holds 21.69 million shares, MCGUIRE TERRANCE has 3.07 million shares and Andersen Jill has 181.74 thousand shares. Over the past six months, insider transactions show net selling. They sold 227.17 thousand shares across 10 transactions.

Invivyd, Inc. generated EPS of -$0.47 over the past year. Five-year average earnings growth is -24.99%. Wall Street analysts project EPS growth of 48.75% annually over the next five years. The latest quarter delivered EPS of -$0.06. The next quarter is forecast at -$0.08. Next year's EPS is expected at $49.19. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 13 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $10.00 to $1.00. The high target offers 541.03% upside. The low target suggests -35.9% downside. The mean target is $7.00. This offers 348.72% upside. Invivyd, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended November 06, 2025, missed forecasts by 23.06%. The prior quarter beat by 200.0%. Over the last six quarters, Apple has recorded several small beats. These include 8.11% in August 14, 2024.

Invivyd, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $4.60. This means the shares are trading below this model’s fair value.

Invivyd, Inc. (NASDAQ:IVVD) closed at $1.56 USD, gaining $0.13 (9.09%) from the previous close of $1.43. The stock is currently mid-range between its 52-week high and low $0.46 and $3.07. With a market capitalization of about $207.06 million, Invivyd, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.61). Key stats such as the average daily volume over the past year has been around 2.85 million shares, in line with its 52-week average. Headquartered in Waltham, MA, Invivyd, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO William E. Duke Jr., the company employs approximately 99 people and listed since August 06, 2021. Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States.

Invivyd, Inc. trades at a P/E ratio of -5.06, slightly below the S&P 500 average, with a price-to-sales ratio of 3.83 and a price-to-book ratio of 1.1 suggesting the stock is closer to book value. The P/FCF stands at -3.51, also below market averages.

Invivyd, Inc. (NASDAQ:IVVD) shares are flat -9.31% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Invivyd, Inc. trading at a premium to the broader market with a P/E of -5.06. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $7.75, suggesting 396.79% upside. Our AI forecast model points to short-term weakness (-7.05% over two weeks), a medium-term rise (50.64% over three months), and a longer-term gain (620.51% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Invivyd, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -7.05%, with price expected at $1.45 by April 07, 2026, within a range of $1.29 to $1.61 3-Month Outlook: Projected rise of 50.64%, reaching $2.35 by June 22, 2026, with a range of $2.28 to $2.42. 1-Year Outlook: Projected gain of 620.51%, with price at $11.24 by March 24, 2027, within a range of $3.75 to $18.99.